PCAF-primed EZH2 acetylation regulates its stability and promotes lung adenocarcinoma progression

Nucleic Acids Research

Volumn 43, Issue 7, 2015, Pages 3591-3604

  Wan, Junhu ^a,b   Zhan, Jun ^a,b   Li, Shuai ^a,b   Ma, Ji ^a,b   Xu, Weizhi ^a,b   Liu, Chang ^a,b   Xue, Xiaowei ^a,b   Xie, Yuping ^c   Fang, Weigang ^a,b   Chin, Y Eugene ^d   Zhang, Hongquan ^a,b  

^a Amsterdam   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c TSINGHUA UNIVERSITY   (China)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE ACETYLTRANSFERASE PCAF; LYSINE; POLYCOMB REPRESSIVE COMPLEX 2; SIRTUIN 1; TRANSCRIPTION FACTOR EZH2; EZH2 PROTEIN, HUMAN; P300-CBP-ASSOCIATED FACTOR; SIRT1 PROTEIN, HUMAN;

ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CONTROLLED STUDY; DEACETYLATION; EMBRYO; GENE REPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ACETYLATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; TUMOR INVASION; ACETYLATION; ADENOCARCINOMA; DISEASE COURSE; GENE SILENCING; GENETICS; HEK293 CELL LINE; LUNG TUMOR; MASS SPECTROMETRY; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ACETYLATION; ADENOCARCINOMA; CELL LINE, TUMOR; DISEASE PROGRESSION; GENE SILENCING; HEK293 CELLS; HUMANS; LUNG NEOPLASMS; MASS SPECTROMETRY; NEOPLASM METASTASIS; P300-CBP TRANSCRIPTION FACTORS; POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN STABILITY; SIRTUIN 1;

EID: 84930505960     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkv238     Document Type: Article

References (42)

1. Kennison, J.A. (1995) The Polycomb and trithorax group proteins of Drosophila: trans-regulators of homeotic gene function. Annu. Rev. Genet., 29, 289-303.
2. Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R.S. and Zhang, Y. (2002) Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science, 298, 1039-1043.
3. Kuzmichev, A., Nishioka, K., Erdjument-Bromage, H., Tempst, P. and Reinberg, D. (2002) Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev., 16, 2893-2905.
4. Muller, J., Hart, C.M., Francis, N.J., Vargas, M.L., Sengupta, A., Wild, B., Miller, E.L., O'Connor, M.B., Kingston, R.E. and Simon, J.A. (2002) Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. Cell, 111, 197-208.
5. Plath, K., Fang, J., Mlynarczyk-Evans, S.K., Cao, R., Worringer, K.A., Wang, H., de la Cruz, C.C., Otte, A.P., Panning, B. and Zhang, Y. (2003) Role of histone H3 lysine 27 methylation in X inactivation. Science, 300, 131-135.
6. Lee, T.I., Jenner, R.G., Boyer, L.A., Guenther, M.G., Levine, S.S., Kumar, R.M., Chevalier, B., Johnstone, S.E., Cole, M.F., Isono, K. et al. (2006) Control of developmental regulators by Polycomb in human embryonic stem cells. Cell, 125, 301-313.
7. Simon, J.A. and Lange, C.A. (2008) Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat. Res., 647, 21-29.
8. Shen, X., Kim, W., Fujiwara, Y., Simon, M.D., Liu, Y., Mysliwiec, M.R., Yuan, G.C., Lee, Y. and Orkin, S.H. (2009) Jumonji modulates polycomb activity and self-renewal versus differentiation of stem cells. Cell, 139, 1303-1314.
9. Varambally, S., Dhanasekaran, S.M., Zhou, M., Barrette, T.R., Kumar-Sinha, C., Sanda, M.G., Ghosh, D., Pienta, K.J., Sewalt, R.G., Otte, A.P. et al. (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature, 419, 624-629.
10. Kleer, C.G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S.A., Ghosh, D., Sewalt, R.G., Otte, A.P., Hayes, D.F. et al. (2003) EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl. Acad. Sci. U.S.A., 100, 11606-11611.
11. Huqun, Ishikawa, R., Zhang, J., Miyazawa, H., Goto, Y., Shimizu, Y., Hagiwara, K. and Koyama, N. (2012) Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer. Cancer, 118, 1599-1606.
12. Behrens, C., Solis, L.M., Lin, H., Yuan, P., Tang, X., Kadara, H., Riquelme, E., Galindo, H., Moran, C.A., Kalhor, N. et al. (2013) EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma. Clin. Cancer Res., 19, 6556-6565.
13. Chen, H., Tu, S.W. and Hsieh, J.T. (2005) Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J. Biol. Chem., 280, 22 437-22 444.
14. Yu, J., Cao, Q., Mehra, R., Laxman, B., Yu, J., Tomlins, S.A., Creighton, C.J., Dhanasekaran, S.M., Shen, R., Chen, G. et al. (2007) Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell, 12, 419-431.
15. Kotake, Y., Cao, R., Viatour, P., Sage, J., Zhang, Y. and Xiong, Y. (2007) pRB family proteins are required for H3K27 trimethylation and Polycomb repression complexes binding to and silencing p16INK4alpha tumor suppressor gene. Genes Dev., 21, 49-54.
16. Agherbi, H., Gaussmann-Wenger, A., Verthuy, C., Chasson, L., Serrano, M. and Djabali, M. (2009) Polycomb mediated epigenetic silencing and replication timing at the INK4a/ARF locus during senescence. PLoS One, 4, e5622.
17. Bracken, A.P., Pasini, D., Capra, M., Prosperini, E., Colli, E. and Helin, K. (2003) EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplifed in cancer. EMBO J., 22, 5323-5335.
18. Varambally, S., Cao, Q., Mani, R.S., Shankar, S., Wang, X., Ateeq, B., Laxman, B., Cao, X., Jing, X., Ramnarayanan, K. et al. (2008) Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science, 322, 1695-1699.
19. Bohrer, L.R., Chen, S., Hallstrom, T.C. and Huang, H. (2010) Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: a potential mechanism of androgen-refractory progression of prostate cancer. Endocrinology, 151, 5136-5145.
20. Cha, T.L., Zhou, B.P., Xia, W., Wu, Y., Yang, C.C., Chen, C.T., Ping, B., Otte, A.P. and Hung, M.C. (2005) Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science, 310, 306-310.
21. Chen, S., Bohrer, L.R., Rai, A.N., Pan, Y., Gan, L., Zhou, X., Bagchi, A., Simon, J.A. and Huang, H. (2010) Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. Nat. Cell Biol., 12, 1108-1114.
22. Kaneko, S., Li, G., Son, J., Xu, C.F., Margueron, R., Neubert, T.A. and Reinberg, D. (2010) Phosphorylation of the PRC2 component Ezh2 is cell cycle-regulated and up-regulates its binding to ncRNA. Genes Dev., 24, 2615-2620.
23. Wei, Y., Chen, Y.H., Li, L.Y., Lang, J., Yeh, S.P., Shi, B., Yang, C.C., Yang, J.Y., Lin, C.Y., Lai, C.C. et al. (2011) CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. Nat. Cell Biol., 13, 87-94.
24. Yu, Y.L., Chou, R.H., Shyu, W.C., Hsieh, S.C., Wu, C.S., Chiang, S.Y., Chang, W.J., Chen, J.N., Tseng, Y.J., Lin, Y.H. et al. (2013) Smurf2-mediated degradation of EZH2 enhances neuron differentiation and improves functional recovery after ischaemic stroke. EMBO Mol. Med., 5, 531-547.
25. Chu, C.S., Lo, P.W., Yeh, Y.H., Hsu, P.H., Peng, S.H., Teng, Y.C., Kang, M.L., Wong, C.H. and Juan, L.J. (2014) O-GlcNAcylation regulates EZH2 protein stability and function. Proc. Natl. Acad. Sci. U. S. A., 111, 1355-1360.
26. Latham, J.A. and Dent, S.Y. (2007) Cross-regulation of histone modifcations. Nat. Struct. mol. Biol., 14, 1017-1024.
27. Yang, X.J. and Seto, E. (2008) Lysine acetylation: codifed crosstalk with other posttranslational modifcations. Mol. Cell, 31, 449-461.
28. Zhao, D., Zou, S.W., Liu, Y., Zhou, X., Mo, Y., Wang, P., Xu, Y.H., Dong, B., Xiong, Y., Lei, Q.Y. et al. (2013) Lysine-5 acetylation negatively regulates lactate dehydrogenase A and is decreased in pancreatic cancer. Cancer Cell, 23, 464-476.
29. Xu, Y., Li, F., Lv, L., Li, T., Zhou, X., Deng, C.X., Guan, K.L., Lei, Q.Y. and Xiong, Y. (2014) Oxidative stress activates SIRT2 to deacetylate and stimulate phosphoglycerate mutase. Cancer Res., 74, 3630-3642.
30. Valls, E., de la Cruz, X. and Martinez-Balbas, M.A. (2003) The SV40 T antigen modulates CBP histone acetyltransferase activity. Nucleic Acids Res., 31, 3114-3122.
31. Vaziri, H., Dessain, S.K., Ng Eaton, E., Imai, S.I., Frye, R.A., Pandita, T.K., Guarente, L. and Weinberg, R.A. (2001) hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell, 107, 149-159.
32. Brunet, A., Sweeney, L.B., Sturgill, J.F., Chua, K.F., Greer, P.L., Lin, Y., Tran, H., Ross, S.E., Mostoslavsky, R., Cohen, H.Y. et al. (2004) Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science, 303, 2011-2015.
33. Kuzmichev, A., Margueron, R., Vaquero, A., Preissner, T.S., Scher, M., Kirmizis, A., Ouyang, X., Brockdorff, N., Abate-Shen, C., Farnham, P. et al. (2005) Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc. Natl. Acad. Sci. U.S.A., 102, 1859-1864.
34. Wu, S.C. and Zhang, Y. (2011) Cyclin-dependent kinase 1 (CDK1)-mediated phosphorylation of enhancer of zeste 2 (Ezh2) regulates its stability. J. Biol. Chem., 286, 28511-28519.
35. Chase, A. and Cross, N.C. (2011) Aberrations of EZH2 in cancer. Clin. Cancer Res., 17, 2613-2618.
36. Schreiber, S.L. and Bernstein, B.E. (2002) Signaling network model of chromatin. Cell, 111, 771-778.
37. Brooks, C.L. and Gu, W. (2003) Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr. Opin. Cell Biol., 15, 164-171.
38. Matsuzaki, H., Daitoku, H., Hatta, M., Aoyama, H., Yoshimochi, K. and Fukamizu, A. (2005) Acetylation of Foxo1 alters its DNA-binding ability and sensitivity to phosphorylation. Proc. Natl. Acad. Sci. U.S.A., 102, 11278-11283.
39. Kramer, O.H., Knauer, S.K., Greiner, G., Jandt, E., Reichardt, S., Guhrs, K.H., Stauber, R.H., Bohmer, F.D. and Heinzel, T. (2009) A phosphorylation-acetylation switch regulates STAT1 signaling. Genes Dev., 23, 223-235.
40. Morey, L. and Helin, K. (2010) Polycomb group protein-mediated repression of transcription. Trends Biochem. Sci., 35, 323-332.
41. Crea, F., Paolicchi, E., Marquez, V.E. and Danesi, R. (2012) Polycomb genes and cancer: time for clinical application? Crit. Rev. Oncol. Hematol., 83, 184-193.
42. Xu, C., Hou, Z., Zhan, P., Zhao, W., Chang, C., Zou, J., Hu, H., Zhang, Y., Yao, X., Yu, L. et al. (2013) EZH2 regulates cancer cell migration through repressing TIMP-3 in non-small cell lung cancer. Med. Oncol., 30, 713.